Administration of Bamlanivimab

{
  "compose" : {
    "exclude" : [ ],
    "include" : [ {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "extension" : [ {
        "extension" : [ {
          "valueString" : "concept",
          "url" : "path"
        }, {
          "url" : "count",
          "valueInteger" : 2
        } ],
        "url" : "http://health-samurai.io/extensions/excised-data"
      } ]
    } ]
  },
  "date" : "2023-06-21T18:16:37-04:00",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2022-07-14T01:03:32.000-04:00",
    "profile" : [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ]
  },
  "publisher" : "Clinical Architecture",
  "jurisdiction" : [ {
    "extension" : [ {
      "valueString" : "UNKNOWN",
      "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason"
    } ]
  } ],
  "purpose" : "(Clinical Focus: This set of values contains terms related to administration of bamlanivimab.),(Data Element Scope: ),(Inclusion Criteria: Includes introduction of bamlanivimab into central or peripheral veins via open or percutaneous routes.),(Exclusion Criteria: Excludes administration of other monoclonal antibodies (e.g., abciximab, infliximab) and routes of administration that do not involve open or percutaneous procedures (i.e. oral administration).)",
  "name" : "AdministrationOfBamlanivimab",
  "experimental" : false,
  "resourceType" : "ValueSet",
  "expansion" : {
    "contains" : [ {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "XW033F6",
      "display" : "Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6",
      "version" : "2023"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "XW043F6",
      "display" : "Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6",
      "version" : "2023"
    } ],
    "offset" : 0,
    "total" : 2,
    "identifier" : "urn:uuid:0ddb55cd-21e9-479e-a7f5-b276dac10cbd",
    "timestamp" : "2023-06-29T15:32:24-04:00",
    "parameter" : [ {
      "name" : "count",
      "valueInteger" : 1000
    }, {
      "name" : "offset",
      "valueInteger" : 0
    } ]
  },
  "title" : "Administration of Bamlanivimab",
  "extension" : [ {
    "valueString" : "Clinical Architecture",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author"
  }, {
    "valueDate" : "2023-06-21",
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate"
  }, {
    "valueDate" : "2022-07-14",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate"
  }, {
    "url" : "http://health-samurai.io/extensions/source",
    "valueCode" : "db"
  } ],
  "status" : "active",
  "id" : "25772746-bf6c-42b7-97f6-84f84ab3b96c",
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4026",
  "identifier" : [ {
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113883.3.3616.200.110.102.4026"
  } ],
  "version" : "20220714"
}